Zai Lab (NASDAQ:ZLAB) CFO Sells $31,726.89 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 1,703 shares of Zai Lab stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $18.63, for a total value of $31,726.89. Following the completion of the sale, the chief financial officer directly owned 19,999 shares in the company, valued at $372,581.37. This represents a 7.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Zai Lab Price Performance

Shares of Zai Lab stock opened at $18.83 on Thursday. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of -11.70 and a beta of 0.85. The stock’s 50-day moving average is $18.69 and its 200-day moving average is $22.84. Zai Lab Limited Unsponsored ADR has a one year low of $15.96 and a one year high of $44.34.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.02). Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The firm had revenue of $127.60 million for the quarter, compared to the consensus estimate of $122.67 million. On average, equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ZLAB shares. JPMorgan Chase & Co. lowered their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday. UBS Group started coverage on shares of Zai Lab in a report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. Zacks Research lowered shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.00.

Hedge Funds Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. 41.65% of the stock is owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.